Skip to content
Peptide research

DSIP

Also known as Delta Sleep-Inducing Peptide
Category
Specialized Research
Administration routes
Injectable
Regulatory status
Not FDA-approved

What it is

A synthetic nine-amino-acid peptide marketed to promote deep, delta-wave sleep, with secondary claims for stress, pain, and hormone balance. The evidence is thin: small human studies suggest a modest sleep benefit, while the other uses rest on animal and mechanism data. There is no long-term clinical safety data, and, unusually, no receptor or gene for it has been identified. Not an approved drug in the US, and most supply is unregulated research-grade.

Read Full record

Studied uses & evidence

Studied uses(7)

  • Sleep quality improvement

    Medium

    A small double-blind trial found modestly shorter sleep latency, though effects were weak and unreplicated.

  • Stress response modulation

    Low

    Animal data suggest HPA-axis calming, but human results are mixed with no clinical trial.

  • Pain reduction

    Low

    Strong rodent painkilling data, but human evidence is one small uncontrolled 1984 pilot.

Evidence limits

Evidence Level
Preliminary

Clinical evidence for DSIP spans several small human trials (typically 7-16 subjects) conducted primarily in the 1980s-1990s, with contradictory results for sleep promotion. Withdrawal and pain findings are also preliminary, relying largely on uncontrolled studies. No large-scale randomized controlled trials have been conducted. The peptide's gene, receptor, and precursor remain unidentified, limiting mechanistic understanding.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

Do not use if

  • Epilepsy

    Moderate

    DSIP modulates GABA and sleep-wake neurotransmission. May interact unpredictably with seizure thresholds.

General cautions

  • Pregnancy

    Absolute

    No safety data.

Risk summary(6)

Risks = level of concern: High · Moderate · Low · Theoretical

  • Long-term safety has not been established in any clinical research study

    High
  • Very short in vitro half-life (~15 minutes) raises bioavailability questions

    Low
  • No identified gene, receptor, or precursor protein; mechanism incompletely understood

    Moderate
  • Headaches, dizziness, GI issues reported anecdotally

    Low
  • Fatigue or excessive lethargy if dose too high or timing wrong

    Low
  • Injection site reactions including redness and mild irritation

    Low
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.